Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
Dermatology and Therapy(2024)
Abstract
For some patients with atopic dermatitis (AD), topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and systemic therapies are inadequate to control disease or are associated with adverse events (AEs). Ruxolitinib cream monotherapy demonstrated anti-inflammatory and anti-pruritic effects among patients enrolled in two pivotal phase 3 studies (TRuE-AD1/TRuE-AD2); most patients had long-term disease control with as-needed use during the 44-week long-term safety (LTS) period. This post hoc analysis explored efficacy and safety of 1.5
MoreTranslated text
Key words
Atopic dermatitis,Eczema,Janus kinases,Ruxolitinib cream,Treatment outcome
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined